Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00102973
Status:
COMPLETED
Last Update Posted:
2012-05-31
First Post:
2005-02-04
Brief Title:
TLK286 Telcyta in Combination With Carboplatin Paraplatin Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
Sponsor:
Telik
Organization:
Telik
Study Overview
Official Title:
Phase III Randomized Study of TLK286 Telcyta in Combination With Carboplatin Paraplatin Versus Liposomal Doxorubicin Doxil as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer ASSIST-3
Status:
COMPLETED
Status Verified Date:
2006-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer fallopian tube cancer or primary peritoneal cancer that is refractory or resistant to platinum chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None